These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 30406885

  • 1. Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting.
    Liel Y, Abu Tailakh M.
    Endocrine; 2019 Mar; 63(3):651-656. PubMed ID: 30406885
    [Abstract] [Full Text] [Related]

  • 2. Risedronate: a new oral bisphosphonate.
    Umland EM, Boyce EG.
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [Abstract] [Full Text] [Related]

  • 3. Midterm outcome of risedronate therapy for patients with Paget's disease of bone in the central part of Japan.
    Nishida Y, Yamada Y, Tsukushi S, Sugiura H, Urakawa H, Ishiguro N.
    Clin Rheumatol; 2013 Feb; 32(2):241-5. PubMed ID: 23138882
    [Abstract] [Full Text] [Related]

  • 4. Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease.
    Hooper M, Faustino A, Reid IR, Hosking D, Gilchrist NL, Selby P, Wu M, Salzmann G, West J, Leung A.
    Osteoporos Int; 2009 Jan; 20(1):141-50. PubMed ID: 18536953
    [Abstract] [Full Text] [Related]

  • 5. Treatment of Paget's disease of bone: a survey of clinical practice in Australia.
    Walsh JP, Attewell R, Stuckey BG, Hooper MJ, Wark JD, Fletcher S, Ferrari V, Eisman JA.
    Bone; 2008 Jun; 42(6):1219-25. PubMed ID: 18353737
    [Abstract] [Full Text] [Related]

  • 6. Bisphosphonates in the management of Paget's disease.
    Ralston SH.
    Bone; 2020 Sep; 138():115465. PubMed ID: 32512166
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M, Reginster JY.
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D, Mossetti G, Viceconti R, Sorrentino M, Nunziata V.
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [Abstract] [Full Text] [Related]

  • 16. Bisphosphonate resistance in Paget's disease of bone.
    Joshua F, Epstein M, Major G.
    Arthritis Rheum; 2003 Aug; 48(8):2321-3. PubMed ID: 12905487
    [Abstract] [Full Text] [Related]

  • 17. Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study.
    Brown JP, Hosking DJ, Ste-Marie L, Johnston CC, Reginster J, Ryan WG, Johnson TD, Bekker PJ.
    Calcif Tissue Int; 1999 Feb; 64(2):93-9. PubMed ID: 9914313
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.